Vaxart stock represents equity ownership shares in Vaxart, Inc., a clinical-stage biotechnology company focused on the discovery and development of proprietary oral vaccines administered via convenient room-temperature stable pills rather than traditional needles. Traded publicly, the stock serves as a financial vehicle for investors to participate in the company's corporate growth while providing Vaxart with essential capital to fund its research operations, regulatory filings, and human clinical trials. Stock performance is tied directly to scientific advancements, clinical trial data readouts, and capital-raising activities.